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Meta-analyses indicate that the gene coding for
the dopamine transporter (DAT1 or SLC6A3) is
associated with an increased risk for ADHD. The
mechanisms of this gene for ADHD are unclear. We
systematically reviewed studies linking the VNTR
in the 30 UTR of the DAT1 to neurophysiological
and neuropsychological measures. In addition, a
broad set of executive/cognitive and motor tests
was administered to 350 children (5–11 years)
and adolescents (11–19 years) with ADHD and 195
non-affected siblings. Two VNTRs (in intron 8 and
the 30 UTR) and four SNPs (two 50 and two 30) in
DAT1 were genotyped. The effect of the poly-
morphisms on neuropsychological functioning
was studied. The review indicated that the major-
ity of studies did not find a relation between DAT1
and neurophysiological or neuropsychological
measures. In our sample, several of the poly-
morphisms of DAT1 were associated with ADHD
and ADHD was associated with impaired neurop-
sychological functioning. However, none of the
DAT1 polymorphisms was convincingly asso-
ciated with neuropsychological dysfunctioning.
This suggests that the effect of DAT1 on ADHD
was not mediated by neuropsychological perfor-
mance. However, since DAT1 is mainly expressed
in the striatum and not the prefrontal cortex, it
may influence striatum-related functions (such as
delay aversion) more heavily than prefrontal
related functions (such as executive functions).
Associations of DAT1 with ADHD were only found
in adolescents, which may suggest that DAT1
mainly exerts its effect in adolescence, and/or that
having a more persistent form of ADHD may mark
a more severe or homogeneous genetic form of the
disorder.  2008 Wiley-Liss, Inc.
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INTRODUCTION
Attention-Deficit/Hyperactivity Disorder (ADHD) [Ameri-
can psychiatric Association, 1994] is strongly heritable. Based
on the results of multiple twin studies conducted worldwide,
ADHD has an estimated heritability of approximately 76%
[Faraone et al., 2005]. Several reviews and meta-analyses have
been published on the involvement of dopaminergic genes in
ADHD [Swanson et al., 2000; Curran et al., 2001; Faraone
et al., 2001, 2005; Maher et al., 2002; Li et al., 2006; Yang et al.,
2007]. Most meta-analyses have shown evidence for the
involvement of genes coding for dopamine receptors 4 and
5 (DRD4 and DRD5, respectively), the gene encoding for the
dopamine transporter (DAT1 or SLC6A3), and the gene coding
for the enzyme dopamine beta-hydroxylase (DBH) [Faraone
et al., 2005]. We focus here on the role of the DAT1 gene in
ADHD, since it is one of the most studied genes in ADHD
[Thapar et al., 2005].
DAT1 is located on chromosome 5p15.3. The most widely
studied polymorphism is a 40 base pair variable number
of tandem repeats (VNTR) polymorphism located in the
30 untranslated region (UTR) of the gene [Maher et al., 2002;
Faraone et al., 2005; Yang et al., 2007]. The number of repeats
ranges between 3 and 13 [Vandenbergh et al., 1992; Nakatome
et al., 1996], with 10 and 9, respectively, being the most
common [Mitchell et al., 2000]. Although this polymorphism is
not located in a translated region of the gene, it may have an
effect on gene expression [Mill et al., 2002]. This has been
investigated in vitro as well as in vivo, with conflicting
results [Madras et al., 2005; Brookes et al., 2007]. It has been
suggested that the 10-repeat allele is associated with an
abnormally active dopamine transporter, resulting in an
increased re-uptake of dopamine and thus in a depletion of
dopamine in the synaptic cleft [Mill et al., 2002]. This may lead
to hypoactivity of the dopaminergic pathways [Yang et al.,
2007]. DAT1 is mainly expressed in the striatum and to a lesser
extent in the prefrontal cortex [Diamond, 2007]. Eliminating
DAT1 gene function in mice increases hyperactivity
and disinhibition [Giros et al., 1996]. However, the exact
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mechanisms of the DAT1 effect on ADHD pathology remain
unclear. Several studies have tried to unravel the modes of
action of DAT1 by studying the association of the gene with
neurophysiological and neuropsychological measures. Neuro-
physiological and neuropsychological measures may function
as endophenotypes (intermediate phenotypes): heritable,
underlying, continuously distributed traits that heighten the
risk for developing a disorder and mediate between genotype
and phenotype [Gottesman and Gould, 2003]. Endophenotypes
are proposed to be more heritable than phenotypes because
they are etiologically ‘‘closer’’ to the disease genes than pheno-
types and offer the advantage of a quantitative trait instead
of dichotomous entities like DSM diagnostic categories
[Gottesman and Gould, 2003]. Therefore, focusing on neuro-
physiological and neuropsychological measures in relation to
DAT1 in ADHD may provide insight into the pathways leading
from DAT1 to ADHD.
Review of Studies Linking DAT1 to Neurophysiological
and Neuropsychological Measures
An overview of the studies cited here is provided in Table I.
Most studies have compared the 10/10 genotype of the 30 UTR
VNTR with the 9/10 and 9/9 genotypes. The results are
inconsistent and tend to suggest no significant association of
the VNTR with neurophysiological and neuropsychological
measures. With respect to IQ, one study reported that the 10/10
genotype was associated with a lower IQ in two independent
samples of ADHD children, but not in controls, suggesting a
common genetic basis for ADHD and low IQ [Mill et al., 2006].
However, this finding has not been replicated by a study using
a substantially larger sample of ADHD children and their non-
affected siblings nor in a study of affected sib-pairs from
251 families [Sonuga-Barke et al., 2008; Loo et al., submitted].
Three other studies using non-ADHD subjects found no
relation between DAT1 and IQ either [Ball et al., 1998; Rueda
et al., 2005; Genro et al., 2006]. Therefore, most studies suggest
no relation between DAT1 and IQ.
The three largest studies (N¼ 540, N¼ 146, and N¼ 122)
exploring several neuropsychological functions (attention and
several executive functions) in relation to DAT1 in ADHD
found no or only few associations [Barkley et al., 2006; Wohl
et al., 2008; Loo et al., submitted]. No differences were reported
in the largest study between ADHD adolescents and adults
with the 10/10 genotype and ADHD adolescents and adults
with the 9/10 genotype on 14 of 15 variables [Barkley et al.,
2006]. On one variable of inhibition, the 10/10 genotype
performed more poorly than the 9/10 genotype. The second
largest study did not find differences between the 10 allele and
9 allele on measures of inhibition and cognitive flexibility
[Wohl et al., 2008]. The other study did not find any differences
between carriers of the 10/10 genotype and others on 14 of 14
variables, except for one interaction (10/10 in combination with
ADHD in the mother related to poorer set-shifting) [Loo et al.,
submitted]. Several other studies, utilizing substantially
smaller samples (N< 100), also reported mainly negative
results. One study found no effect of DAT1 on 10 of 10 working
memory variables, though the 10/10 genotype appeared
related to poorer (selective) attention (1 of 4 measures) and
inhibition (1 of 1 measure) [Cornish et al., 2005]. Furthermore,
no relation was found between DAT1 and 24 of 25 variables
measuring several executive and non-executive functions,
except for 1 of 4 measures of inhibition: Adults with the
10/10 genotype contrarily displayed a better inhibition than
adults with other genotypes [Boonstra et al., 2007]. Negative or
contrary findings were also reported in two other studies, who
found no effects of DAT1 on 2 of 3 measures of vigilance and
15 of 16 measures of attention, except for the one finding that
individuals with the 10/10 genotype committed fewer errors
than individuals with the 9/10 and 9/9 genotype and less
omission errors in the first quarter of a test of attention [Oh
et al., 2003; Kim et al., 2006]. In addition, no differences were
reported between the 10/10 genotype and other genotypes for
regional blood flow during a vigilance task [Szobot et al., 2005].
Similar negative or contrary findings were found when the
effect of DAT1 (10/10 vs. other genotypes) was studied in
healthy individuals. One study found no effect on 4 of
4 measures of attention [Fossella et al., 2002]; another study
found no effect on 8 of 8 measures of episodic memory, although
the 10/10 genotype had less midbrain activation during task
performance [Schott et al., 2006]; another study found no effect
on 2 of 4 measures of attention and a reversed effect on the
other 2 (10/10 performing better on a conflict task and showing
stronger ERPs) [Rueda et al., 2005]; another study found no
effect of DAT1 on ERPs (except for a stronger gamma response
to target stimuli in 10/10 genotype controls) [Demiralp et al.,
2007].
The findings reported above suggest that DAT1 is not
associated with neuropsychological and neurophysiological
abnormalities frequently reported in ADHD. However, some
studies did report a relation of DAT1 with these measures. In
two studies, the same authors found that ADHD children
with the 10/10 genotype displayed an abnormal reduction in
attentional asymmetry (i.e., reduced leftward inattention) and
increased response variability compared to affected children
with other genotypes [Bellgrove et al., 2005a,b]. The same
authors also reported that normal children with the 10/10
genotype (or the 3/3 (now called 6/6) genotype in intron 8 which
is in moderate linkage disequilibrium with the VNTR in the
30 UTR) displayed inattention for left-sided stimuli [Bellgrove
et al., 2007]. Other researchers found abnormalities in
vigilance and EEG activity in response to methylphenidate in
ADHD affected children with the 10/10 genotype [Loo et al.,
2003]. In addition, one study reported that the 10/10 genotype
had no effect on performance on an inhibition task in children
with ADHD, their non-affected siblings and controls, yet the
10/10 genotype was associated with lower activation patterns
in the striatum during the task in children with ADHD and
their non-affected siblings, but not controls [Durston et al.,
2008]. The authors suggest that DAT1 gene effects in the
striatum may be involved in translating the genetic risk of
ADHD into a neurobiological substrate.
Although the majority of studies report no effects of DAT1
on neurophysiological and neuropsychological measures,
methodological aspects may have contributed significantly to
the observed pattern of results. For example, differences in
ascertainment (different ADHD subtypes, including controls
or not), differences in ADHD measurement methods (interview
of questionnaires), sampling (clinically referred or not),
participants characteristics (such as age, sex, and comorbidity)
and the focus on a single polymorphism are plausibly related to
null effects. Given that some effects of DAT1 on neuro-
physiological and neuropsychological measures have been
found, further research is needed to understand the nature
and extent of these effects.
Current Study on the Relation Between DAT1 and
Neuropsychological Measures in ADHD
We sought to improve upon previous studies described above
in several respects. First, we recruited a large sample of ADHD
subjects (N¼ 350). Most previous studies have utilized much
smaller samples, increasing the chance of obtaining spurious
results. We further extended our sample with 195 non-affected
siblings of ADHD children. Second, we analyzed the effect of
DAT1 separately for children and adolescents, since we
expected to find stronger effects of DAT1 in adolescents. Levels
of dopamine decrease with age and the effect of the DAT1
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genotype may, therefore, be stronger in adolescents compared
to children [Barkley et al., 2006]. For example, one study
reported that the effects of DAT1 on phenotypical measures of
ADHD were stronger, when the longitudinally followed sample
was studied in adolescence and adulthood compared to
childhood [Barkley et al., 2006]. Third, we applied a broad
neuropsychological battery covering not only executive/cogni-
tive functions, but also motor functions. Previous studies have
shown that DAT1 mainly effects dopamine neurotransmission
in the basal ganglia and midbrain, but less in the prefrontal
cortex [Durston et al., 2005; Schott et al., 2006; Diamond, 2007;
Scherk et al., 2007]. Therefore, we expected that the effect of
DAT1 was on motor measures and not (or to a lesser extent) on
executive/cognitive measures. Fourth, almost all previous
studies except two have studied only the effect of the VNTR
in the 30 UTR of DAT1 [Bellgrove et al., 2007; Sonuga-Barke
et al., 2008]. Although this polymorphism may influence gene
expression [Mill et al., 2002], this is not a well established
finding [Thapar et al., 2005; Brookes et al., 2007]. The VNTR in
the 30 UTR may also be in linkage disequilibrium with the true
functional polymorphism [Brookes et al., 2006; Asherson et al.,
2007]. Therefore, we applied a more thorough investigation of
the DAT1 effect on neuropsychological measures, by genotyp-
ing 6 polymorphisms (VNTR in the 30 UTR, VNTR in intron 8, 2
SNPs in the 50 flanking region, 1 SNP in intron 10 and 1 SNP in
intron 13). Two haplotypes (combination of alleles transmitted
together) were formed, one from the VNTRs, one from the
SNPs, which allowed for robust analyses of the DAT1 effect,
since the haplotypes might tag other variants that are not
directly tested [Sklar, 2005] and may be more strongly
associated with disease or trait than individual polymorphisms
[Barr et al., 2001].
In order to examine the neuropsychological mechanisms of
DAT1 in ADHD, we first confirmed the association between
polymorphisms in DAT1 with ADHD diagnosis in our sample.
The association between ADHD diagnosis and neuropsycho-
logical dysfunction was confirmed [Rommelse et al., 2007a,b,c,
2008a,b]. Thereafter, we went on to examine the association
between risk polymorphisms in DAT1 and neuropsychological
dysfunctions.
MATERIALS AND METHODS
Subjects
Participants were recruited through child psychiatric clinics
in the Dutch part of the International Multicenter ADHD
Genetics (IMAGE) study that aims to identify genes that
increase the risk for ADHD using QTL linkage and association
strategies [Brookes et al., 2006]. A total of 238 families with at
least one child with the combined subtype of ADHD (proband)
and at least one additional sibling (regardless of possible
ADHD-status) participated. This resulted in the participation
of an additional 112 affected siblings (64 with combined
subtype, 28 with inattentive subtype and 20 with hyper-
active-impulsive subtype) and 195 non-affected siblings. Two
groups were formed: one group of affected participants
(N¼ 350, M age¼ 12.0, % boys¼ 75.7, T-score ADHD Total
Conners’ parent¼ 74.2, T-score ADHD Total Conners’
teacher¼ 67.8) and one group of non-affected participants
(N¼ 195, M age¼ 11.5, % boys¼ 45.6, T-score ADHD Total
Conners’ parent¼ 48.1, T-score ADHD Total Conners’
teacher¼ 48.1). Non-affected siblings did not differ from
control in Conners’ ADHD measures [see Rommelse et al.,
2007b]. All subjects were between the ages of 5 and 19 years old
and were of European Caucasian descent. Participants were
excluded, if they had an IQ< 70, a diagnosis of autism,
epilepsy, brain disorders or known genetic disorders, such as
Down syndrome or Fragile-X-syndrome.
The screening procedures and measures for phenotyping
have been described previously [Brookes et al., 2006; Lasky-Su
et al., 2007]. Briefly, screening questionnaires (parent and
teacher Conners’ long version rating scales [Conners, 1996]
and parent and teacher Strengths and Difficulties Question-
naires [Goodman, 1997]) were used to identify subjects with
ADHD symptoms. Scores were considered clinical if T-scores
on Conners’ ADHD-subscales (DSM-IV Inattention, DSM-IV
Hyperactive-Impulsive, and DSM-IV ADHD Total) were 63
or scores on the SDQ-hyperactivity scale were >90th percen-
tile. Additionally, the Parental Account of Children’s Symp-
toms (PACS) [Taylor, 1986] was administered to subjects
scoring clinically on any of the questionnaires. Impairment
was determined as significant if functioning was impaired in
home situations and/or at school. For diagnostic purposes, data
of the questionnaires and the PACS were subjected to a
standardized algorithm to derive each of the 18 DSM-IV ADHD
symptoms, providing operational definitions for each behav-
ioral symptom [Rommelse et al., 2007a].
Neuropsychological Tasks
The ten neuropsychological tasks used in this study have
been described and analyzed elsewhere [Rommelse et al.,
2007a,b,c, 2008a,b] and are presented in Table II. Missing data
was less than 5% for all variables, except for the Stop task
(9%). Based on previous results [Rommelse et al., 2007a,b,c,
2008a,b], the variable for each task, which showed the most
optimal results in the endophenotypic analyses, was chosen for
TABLE II. Description of the Neuropsychological Tasks
Task Aim of measurement Dependent variable
Executive/cognitive tasks
Stop task Inhibition Stop signal reaction time (SSRT)
Shifting attentional set Inhibition and cognitive flexibility Percentage of errors
Time test Time reproduction Accuracy (total absolute deviation between
stimulus and response)
Visuo-spatial sequencing Visuo-spatial working memory Number of correct targets in the correct
order
Digit span Verbal working memory Digit span backwards
Motor tasks
Pursuit Motor control under continuous adaptation Precision
Tracking Motor control without continuous adaptation Precision
Tapping Self-generated motor output Variability in tapping rate
Baseline speed Motor output as response to external cue Variability in reaction times
Motor timing Timing of motor output Variability in reaction times
Full description of the tasks can be found in Rommelse et al. 2007a,b,c, 2008a,b].
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analysis. All variables were normalized and standardized
using a Van der Waerden transformation (Statistical Package
for the Social Sciences version 14). To obtain a robust measure
of overall neuropsychological functioning with less error
variance than the individual task measures, a principal
component analysis was performed on the ten task variables.
All ten task measures related to one major component,
explaining 47% of the variance in the task measures [see
Rommelse et al. 2008c for more detail].
DNA Extraction and DAT1 Genotyping
An elaborate description of DNA extraction and (DAT1)
genotyping is provided elsewhere [Brookes et al., 2006].
Briefly, DNA was extracted directly from blood samples or cell
lines at Rutgers Cell line and DNA repository in the US. Two
VNTRs and four single nucleotide polymorphisms (SNPs),
which had been genotyped in earlier studies in the IMAGE
sample and had shown association with ADHD in this
sample were selected for the current study [Brookes et al.,
2006; Asherson et al., 2007]. The two VNTRs (40 bp VNTR in
the 30 UTR and 30 bp VNTR in intron 8) had been genotyped in
a sample of 1168 IMAGE families, which included 220 of the
Dutch families that were part of the current study. Genotyping
had been performed using standard polymerase chain reaction
(PCR) protocols and visualization of amplified products on
2% agarose gels as described before [Brookes et al., 2005]. The
four SNPs (rs2550946, rs11564750, rs3776513, and rs40184)
had been genotyped in a sample of 1050 IMAGE families,
including 184 Dutch families from this study. Genotyping had
been done using the Illumina Golden Gate AssayTM (Illumina,
Inc., San Diego, CA) [Brookes et al., 2006], ABI SNPlex
(rs3776513) [Tobler et al., 2005] and ABI TaqMan (rs2550946,
rs11564750, and rs40184) genotyping platforms (Applied
Biosystems, Foster City, CA) [for more details see Brookes
et al., 2008]. See Figure 1 for linkage disequilibrium between
the polymorphisms.
VNTR genotypes were available for 89.3% of the subjects
and we estimated the missing genotypes using haplo.stats
[Sinnwell and Schaid, 2005]. Briefly, haplo.stats estimates
haplotype frequencies and posterior probabilities of haplotype
pairs for a subject, conditional on the observed marker data
[Schaid et al., 2002]. Eight different VNTR haplotypes were
present in the sample based on the VNTR in the 30 UTR and
the VNTR in intron 8 (Table III). The risk 10-6_10-6 diplotype
was present in 52.5% of the sample. A diplotype was defined as
a pair of haplotypes from a given participant: one haplotype
received from each parent. Thus, a participant has only
one diplotype. Genotypes of all four SNPs were available for
344 subjects (63.1%). Since the proportion of missing genotypes
may increase with the number of SNPs available in our
data set, we decided not to estimate missing data for this set
of markers given the fact that the posterior probability for a
genotype may be greatly reduced. Twelve different SNP
haplotypes were found in the sample based on two SNPs in
the 50 flanking region, one SNP in intron 10 and one SNP in
intron 13 (Table III). The haplotype which had increased the
risk for ADHD in an earlier study (XXGC_XXGC) [Brookes
et al., 2008] was present in 25.6% of the sample.
Fig. 1. Linkage disequilibrium values determined by D’ (left panel) and r2 (right panel). [Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
TABLE III. DAT1 Haplotype Frequency in the Entire Sample
Haplotype %
VNTR haplotype
10-6 72.7
9-5 13.4
9-6 7.2
10-5 4.2
10-9 1.1
11-9 0.7
11-6 0.5
8-6 0.3
100.0
SNP Haplotype
GGGC 35.8
AGGT 16.3
GGTT 11.0
AGGC 10.9
GGGT 9.6
AGTT 6.7
ACGC 4.9
ACGT 3.3
GGTC 0.9
ACTC 0.4
AGTC 0.1
GCGC 0.1
100.0
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Data Analysis
Hardy–Weinberg equilibrium (HWE) proportions were
estimated from parental DAT1 genotype information using
the Markov–Chain Monte-Carlo approximation of the exact
test implemented in the GENEPOP package V 3.3 [Raymond
and Rousset, 1995]. No deviations from HWE were detected for
any of the polymorphisms (df¼ 2, P values between 0.061 and
0.500).
Association tests for the single markers were based on
comparison of the risk genotype with a group consisting of all
other genotypes. For this, the risk haplotype was defined as the
genotype that had shown association with ADHD in earlier
studies with a group of all other genotypes [Brookes et al., 2006,
2008; Asherson et al., 2007]. In order to test the association
between DAT1 and ADHD in our sample, we analyzed whether
affected and non-affected siblings differed in proportions of
risk and non-risk genotypes on the six individual markers and
in the proportion of risk and non-risk diplotype transmission
using w2 comparisons.
The association between ADHD and poor neuropsycholog-
ical test performance was analyzed using linear mixed models
with diagnosis as between group factor, age as covariate, and
family structure as random effect to account for within
family correlation [Rommelse et al., 2007a,b,c, 2008a,b]. An
aggregated neuropsychological component was used as
dependent measure of overall neuropsychological functioning.
The association of DAT1 with neuropsychological per-
formance was analyzed using a linear mixed model with
DAT1 as factor (risk vs. non-risk genotypes/diplotypes), age as
covariate, and family structure as random effect. The aggre-
gated neuropsychological component was used as dependent
measure.
All analyses were conducted first for all participants, and
repeated after splitting the sample by median age (children
<11.5 years and adolescents >11.5 years), since previous
studies had shown that the relation of genetic risk markers
with neuropsychological functioning as well as ADHD diag-
nosis is not constant across age [Barkley et al., 2006; Elia and
Devoto, 2007]. Correction for multiple comparisons according
to the False Discovery Rate (FDR) controlling procedure
was applied to the analyses with a q-value setting of
0.05 [Benjamini and Hochberg, 1995].
RESULTS
Association of DAT1 With ADHD Diagnosis
As shown in Table IV, significant findings were restricted to
the adolescent sample after correction for multiple testing:
three single risk markers (10/10 genotype in 30 UTR VNTR, GG
in intron 10 and CC in intron 13) and both risk diplotypes
(10-6_10-6 and XXGC_XXGC) were more common in affected
adolescents compared to non-affected adolescents. Also, the
co-occurrence of the two risk diplotypes together was more
common in affected than in non-affected adolescents
(Table IV), which was at least partly due to the linkage
disequilibrium between the VNTRs and the 30 SNPs (Fig. 1).
Association of ADHD Diagnosis With
Neuropsychological Performance
As previously reported [Rommelse et al., 2007a,b,c, 2008a,b],
affected siblings also performed more poorly on the neuro-
psychological tasks than their non-affected siblings (F (1,
329.4)¼ 32.90, P< 0.001). This result was robust, when
analyses were repeated for children and adolescents, sepa-
rately (F (1, 196.0)¼ 21.54, P< 0.001 and F (1,190.7)¼ 23.00,
P< 0.001), indicating ADHD diagnosis to be associated with
poorer neuropsychological performance within families.
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Association of DAT1 With an Aggregated
Neuropsychological Measure
As shown in Table V, no effect on neuropsychological
performance was found for any of the single markers or
diplotypes, neither in the whole sample nor in the separate
analyses in children or adolescents. Thus, the single markers
and diplotypes that showed association with the ADHD
diagnosis in adolescents were not related to impaired neuro-
psychological functioning. Moreover, the siblings with the
highest possible risk (those with both risk diplotypes) did not
differ from other siblings in neuropsychological performance.
Additional Analyses
A clear pattern of results emerged: DAT1 was associated
with ADHD, ADHD was associated with impaired neuro-
psychological performance, but DAT1 was not associated with
impaired neuropsychological performance. To further sub-
stantiate these findings, we sought to reject the hypothesis that
we missed a relationship between DAT1 and neuropsycholog-
ical performance due to three possibilities.
Possibility 1: DAT1 is only associated with specific
neuropsychological measures and not an overall
neuropsychological measure. If DAT1 were associated
with specific neuropsychological functions, the overall meas-
ure we used might have clouded this relation. Therefore, we
repeated the analyses, as described above, for each of ten
neuropsychological measures. An additional 270 statistical
tests were performed. Of the 90 statistical tests in the entire
sample, only two were nominally significant, which is a finding
one would expect to find by chance and did not survive multiple
testing. Interestingly, though, the two tests showed similar
results: a risk genotype (6/6 in intron 8), and the combination of
risk diplotypes (10-6_10-6 with XXCG_XXCG) were associated
with increased variability of motor timing (F (1, 470.7)¼ 4.63,
P¼ 0.03; F (1, 322.0)¼ 4.60, P¼ 0.03). In the child subsample,
also only two of 90 statistical tests were nominally significant
and did not survive multiple testing correction: one risk
marker (SNP rs3776513 in intron 10) was associated with a
poorer neuropsychological score (Tapping: F (1, 159.0)¼ 4.55,
P¼ 0.04), another risk marker (SNP rs2550946 in the
50 flanking region) was associated with a better neuropsycho-
logical score (Motor Timing: F (1, 143.9)¼ 5.48, P¼ 0.02). In the
adolescent subgroup, two significant and six nominally
significant associations emerged. Two of these six findings
were described above (i.e., risk markers associated with
increased motor timing variability, P values in the adolescent
subsample were 0.007 [significant] and 0.04, respectively).
Three of the other four associations were for a DAT1 marker
(SNP rs11564750 in the 50 flanking region) that had not
shown association with ADHD in adolescents (Pursuit: F (1,
167.4)¼ 4.42, P¼ 0.04; Tracking: F (1, 174.2)¼ 8.43, P¼ 0.004
[significant]; Motor Timing: F (1, 143.4)¼ 4.20, P¼ 0.04).
Therefore, these associations do not shed light on the function
of DAT1 in relation to ADHD. The other nominally significant
finding was for the GG genotype in intron 10 and poorer
accuracy in Tracking (F (1, 174.3)¼ 4.15, P¼ 0.04). The results
indicate a lack of association between DAT1 and an aggregated
neuropsychological factor was most likely not due to a specific
relation between DAT1 and a neuropsychological functioning
that was overlooked in the former analyses.
Possibility 2: DAT1 is only associated with neuro-
psychological performance in non-affected siblings
and not in affected siblings. The non-significant relation
between DAT1 and overall neuropsychological functioning
may be attributable to a differential effect of DAT1 on
neuropsychological functioning in affected and non-affected
subjects. We reasoned that the effect of a gene may be more
purely studied in non-affected siblings than in affected
subjects, since this latter group may have accumulated so
many risk genes and risk environmental factors that the
(small) functional effect of one gene may be obscured. Such a
discrepancy in results has indeed been reported in a MRI-based
study on brain volume (10/10 genotype at the 30 UTR VNTR
showed smaller caudate nucleus volume only in non-affected
siblings and not in affected subjects [Durston et al., 2005]).
Therefore, analyses were repeated separately for affected and
non-affected siblings. Results revealed some nominal associa-
tions between DAT1 and the aggregated score of neuro-
psychological functioning in non-affected siblings and not in
affected siblings. However, these were present only in children
and appeared spurious (data not shown). Thus, the non-
significant relation between DAT1 and the aggregated neuro-
psychological component reported in the main analyses
was not likely due to a differential effect of DAT1 on
neuropsychological functioning in affected and non-affected
subjects.
Possibility 3: DAT1 is only associated with neuro-
psychological performance in subjects without con-
duct disorder and not in subjects with conduct
disorder. Recently, in the larger IMAGE sample we demon-
strated that the association between DAT1 and ADHD was
only significant for subjects without conduct disorder as
opposed to ADHD subjects with conduct disorder [Zhou et al.,
2007]. Since the same may be true for the association between
DAT1 and neuropsychological functioning, we repeated the
analyses for subjects without possible conduct disorder (i.e.,
TABLE V. Association of DAT1 Risk Markers With an Aggregated Neuropsychological
Component Score
DAT1 Test
Overall Children Adolescents
F P F P F P
Single marker
VNTR 30 UTR 10/10 vs. others 0.67 0.42 0.32 0.57 2.58 0.11
VNTR intron 8 6/6 vs. others 0.03 0.86 0.92 0.34 0.79 0.38
SNP rs2550946 GG vs. AA and AG 1.15 0.29 1.15 0.29 0.40 0.53
SNP rs11564750 GG vs. CC and CG 0.77 0.38 0.01 0.97 2.48 0.12
SNP rs3776513 GG vs. TT and TG 0.12 0.73 0.04 0.83 0.62 0.43
SNP rs40184 CC vs. TT and TC 0.29 0.59 0.14 0.71 1.12 0.29
Haplotype
VNTR haplotype 10-6_10-6 vs. others 0.24 0.63 0.35 0.55 1.36 0.25
SNP haplotype XXGC_XXGC vs. others 0.30 0.58 0.12 0.73 1.26 0.26
VNTR and SNP
haplotypes
10-6_10-6 with
XXGC_XXGC vs. others
1.06 0.30 0.00 0.99 1.62 0.21
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75). A total of 109 affected siblings (from the original 350) and
10 non-affected siblings (from the original 195) were excluded
from analyses. None of the DAT1 risk markers was associated
with the aggregated neuropsychological component score,
neither in the overall group nor in the separate subgroups of
children and adolescents (data not shown).
DISCUSSION
A review of studies conducted thus far on the neurophysio-
logical and neuropsychological effects of DAT1 in ADHD (see
column 2 and Table I) demonstrated inconsistent results. Most
studies have compared the 10/10 genotype with other geno-
types of this polymorphism in the 30 UTR and did not find
differences in neurophysiological and neuropsychological
measures. In some cases, ADHD patients with the 10/10
genotype performed worse than ADHD patients with other
genotypes on measures of attentional asymmetry, response
variability, vigilance and EEG activity in response to methy-
lphenidate [Loo et al., 2003; Bellgrove et al., 2005a,b, 2007].
However, contrary findings have also been reported, in which
ADHD patients with the 10/10 genotype performed better than
ADHD patients with other genotypes [Oh et al., 2003; Kim
et al., 2006; Boonstra et al., 2007].
Our study aimed at examining the neuropsychological
mechanisms of DAT1 in ADHD, improving upon previous
studies with respect to sample size and sample composition,
scope of the neuropsychological battery and number of
genotyped polymorphisms in DAT1. The most important
conclusion that can be drawn from our findings is that DAT1
is not associated with the neuropsychological measures used in
this study, even though several risk markers of DAT1 were
associated with ADHD in this sample and ADHD was strongly
related to abnormal neuropsychological functioning. Even the
subjects carrying the highest possible risk (2 risk diplotypes)
did not differ neuropsychologically from subjects with other
diplotypes. The absence of an effect of DAT1 on neuropsycho-
logical measures is in line with the majority of previous studies
[Ball et al., 1998; Fossella et al., 2002; Oh et al., 2003; Rueda
et al., 2005; Szobot et al., 2005; Barkley et al., 2006; Genro et al.,
2006; Kim et al., 2006; Boonstra et al., 2007; Sonuga-Barke
et al., 2008; Wohl et al., 2008; Loo et al., submitted]. It may,
however, be hypothesized that DAT1 has an effect on neuro-
psychological processes not examined in this study or previous
studies, like delay aversion. An altered delay aversion has been
frequently found in ADHD, in which patients are more
motivated to escape or avoid delay than controls [Sonuga-
Barke, 2002]. This altered delay aversion appears not related
to impaired executive/cognitive functions [Sonuga-Barke,
2002, 2005; Toplak et al., 2005], but is related to reduced
striatal activation [Scheres et al., 2007]. Since DAT1 is mainly
expressed in the striatum and to a lesser degree in the
prefrontal cortex [Durston et al., 2005; Schott et al., 2006;
Diamond, 2007; Scherk et al., 2007], DAT1 may have an effect
on striatum related functions (like delay aversion and motor
functions) rather than prefrontal related functions (like
executive functions) [Sonuga-Barke, 2002]. The more detailed
analysis of individual neuropsychological tests also supported
this hypothesis: if there was any association between DAT1
and neuropsychological functioning in our sample, it was
within the domain of motor functioning and not within the
executive/cognitive domain.
We did not find differential effects of DAT1 on neuro-
psychological functioning after stratification of the sample into
affected and non-affected siblings. An effect in non-affected
siblings only, was previously found for DAT1 on the nucleus
caudatus volume [Durston et al., 2005] and for the DRD4 gene
on ADHD in our own studies [Altink et al., 2008]. We also did
not find effects of DAT1 on neuropsychology after stratification
according to the presence or absence of conduct disorder, an
analysis inspired by our findings in the larger IMAGE sample
that showed association of DAT1 with ADHD only in the
absence of conduct disorder [Zhou et al., 2007].
Interestingly, splitting the sample into children and adoles-
cents resulted in nominally significant findings predominantly
in the adolescent group. This may suggest that the effect of
DAT1 on ADHD is not constant across development, but
becomes apparent in late childhood and adolescence [Elia and
Devoto, 2007]. This may be related to the finding that
dopamine levels decrease with increasing age, resulting in a
relatively larger effect of an ‘‘overactive’’ dopamine transporter
on ADHD [Diamond, 2007]. Some support for this hypothesis
has also been reported by Barkley et al. [2006]. They followed
children through adolescence and later through adulthood and
reported that the effect of DAT1 on phenotypic measures of
ADHD increased substantially with increasing age. Given that
the genotype did not differ between measurement moments in
childhood, adolescence, and adulthood, the study of Barkley
et al. [2006] provides preliminary evidence that the effect of
DAT1 on ADHD may be stronger in older subjects with ADHD
compared to younger subjects. However, an alternative
explanation is also possible. It may be that adolescents and
adults with ADHD carry a stronger genetic load or form a
genetically more pure subgroup of ADHD patients than
preadolescent children with ADHD. That is, having a persis-
tent form of ADHD that continues into adolescence and
adulthood may be more heavily related to genetic factors than
a remitting form of ADHD [Faraone et al., 2000].
Limitations
A limitation of this study was that we had SNP data available
for only 63% of the sample (though 89% of the VNTR data was
available). It could be argued that this may have a profound
effect on the power of the study to detect effects of DAT1 and
may explain the negative results of DAT1 on neuropsycho-
logical measures. However, if that would be true, then also no
associations would be expected between the SNPs and ADHD.
This was not the case, two SNPs were associated with ADHD.
Moreover, in theory, the effect of DAT1 on neuropsychological
functioning should be more readily detectable than the effect of
DAT1 on ADHD: neuropsychological measures may act as
endophenotypes, which are hypothesized as stronger linked to
individual genes [Almasy and Blangero, 2001; Castellanos and
Tannock, 2002]. It thus seems implausible that the absence of a
relation between DAT1 and neuropsychological functioning
was attributable to limited power. However, it may be feasible
that DAT1 is associated either with other neuropsychological
traits, or with neuropsychological functioning only in the
presence of particular environmental conditions not accounted
for in the current study. For example, it has been reported that
DAT1 genotype only has an effect on ADHD symptomatology if
the child was exposed to prenatal smoking or if the child grew
up in the context of great psychosocial adversity [Laucht et al.,
2007; Becker et al., 2008]. Not taking into account such
moderating factors may explain the null findings in the review
and analyses described in this article.
CONCLUSION
Several polymorphisms and haplotypes of DAT1
were associated with ADHD in this subsample of IMAGE.
ADHD was also associated with abnormal neuropsychological
functioning. In contrast, DAT1 had no relation to
neuropsychological dysfunction. This suggests that the effect
of DAT1 on the ADHD phenotype is not mediated by neuro-
psychological performance. However, since DAT1 is mainly
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expressed in the striatum and not the prefrontal cortex, DAT1
may influence striatum related functions (like delay aversion
and motor functions) more heavily than prefrontal related
functions (like executive functions). An effect of age seemed
present with several DAT1 risk markers and diplotypes
nominally associated with ADHD in adolescents. This suggests
that the effect of DAT1 on ADHD is not constant across
development, but only becomes apparent in adolescence, and/
or that having a persistent form of ADHD that continues into
adolescence may mark a more severe or homogeneous genetic
form of the disorder.
ACKNOWLEDGMENTS
The authors thank all of the parents, teachers, and children
who participated. We thank Keeley Brookes and Xiaohui Xu for
genotyping. This study was partly funded by a grant to Stephen
Faraone by the National Institute of Mental Health (NIH grant
# R01 MH62873-01A1).
REFERENCES
Almasy L, Blangero J. 2001. Endophenotypes as quantitative risk factors for
psychiatric disease: Rationale and study design. Am J Med Genet
105:42–44.
Altink M, Arias-Va´squez A, Franke B, Slaats-Willemse D, Buschgens C,
Rommelse N, Fliers E, Faraone S, Buitelaar J. 2008. The dopamine
receptor D4 7-repeat allele and prenatal smoking in ADHD affected
children and their unaffected siblings: No gene-environment interac-
tion. J Child Psychol Psychiatry (in press).
American Psychiatric Association. 1994. Diagnostic and statistical manual
of mental disorders, 4th edition. Washington, DC: American Psychiatric
Press.
Asherson P, Brookes K, Franke B, Chen W, Gill M, Ebstein RP, Buitelaar J,
Banaschewski T, Sonuga-Barke E, Eisenberg J, et al. 2007. Confirma-
tion that a specific haplotype of the dopamine transporter gene is
associated with combined-type ADHD. Am J Psychiatry 164:674–677.
Ball D, Hill L, Eley TC, Chorney MJ, Chorney K, Thompson LA, Detterman
DK, Benbow C, Lubinski D, Owen M, et al. 1998. Dopamine markers and
general cognitive ability. Neuroreport 9:347–349.
Barkley RA, Smith KM, Fischer M, Navia B. 2006. An examination of the
behavioral and neuropsychological correlates of three ADHD candidate
gene polymorphisms (DRD4 7þ, DBD TaqI A2, and DAT1 40 bp VNTR)
in hyperactive and normal children followed to adulthood. Am J Med
Genet Part B 141B:487–498.
Barr CL, Xu C, Kroft J, Feng Y, Wigg K, Zai G, Tannock R, Schachar R,
Malone M, Roberts W, et al. 2001. Haplotype study of three poly-
morphisms at the dopamine transporter confirm linkage to attention-
deficit/hyperactivity disorder. Biol Psychiatry 49:333–339.
Becker K, El-Faddagh M, Schmidt MH, Esser G, Laucht M. 2008.
Interaction of dopamine transporter genotype with prenatal smoke
exposure on ADHD symptoms. J Pediatr 152:263–269.
Bellgrove MA, Hawi Z, Kirley A, Fitzgerald M, Gill M, Robertson IH. 2005a.
Association between dopamine transporter (DAT1) genotype, left-sided
inattention, and an enhanced response to methylphenidate in attention-
deficit hyperactivity disorder. Neuropharmocology 30:2290–2297.
Bellgrove MA, Hawi Z, Kirley A, Gill M, Robertson IH. 2005b. Dissecting the
attention deficit hyperactivity disorder (ADHD) phenotype: Sustained
attention, response variability and spatial attentional asymmetries in
relation to dopamine transporter (DAT1) genotype. Neuropsychologia
43:1846–1857.
Bellgrove MA, Chambers CD, Johnson KA, Daibhis A, Daly M, Hawi Z,
Lambert D, Gill M, Robertson IH. 2007. Dopaminergic genotype biases
spatial attention in healthy children. Mol Psychiatry 12:786–792.
Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A
practical and powerful approach to multiple testing. J R Stat Soc B
57:289–300.
Boonstra AM, Kooij JJS, Buitelaar JK, Oosterlaan J, Sergeant JA, Heister
JGAMA, Franke B. 2007. An exploratory study of the relationship
between four candidate genes and neurocognitive performance in adult
ADHD. Am J Med Genet Part B 147B:397–402.
Brookes K, Mill J, Guindalini C, Curran S, Xu X, Knight J, Chen CK, Huang
YS, Sethna V, Taylor E, et al. 2005. A common haplotype of the dopamine
transporter gene associated with attention-deficit/hyperactivity disor-
der and interacting with maternal use of alcohol. Arch Gen Psychiatry
63:74–81.
Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N, Anney R, Franke B, Gill
M, Ebstein R, et al. 2006. The analysis of 51 genes in DSM-IV combined
type attention deficit hyperactivity disorder: Association signals in
DRD4, DAT1 and 16 other genes. Mol Psychiatry 11:934–953.
Brookes KJ, Neale BM, Sugden K, Khan N, Asherson P, D’Souza UM. 2007.
Relationship between VNTR polymorphisms of the human dopamine
transporter gene and expression in post-mortem midbrain tissue. Am
J Med Genet Part B 144B:1070–1078.
Brookes KJ, Xu X, Anney R, Franke B, Zhou K, Chen W, Banaschewski T,
Buitelaar J, Ebstein R, Eisenberg J, et al. 2008. Association of ADHD
with genetic variants in the 50-region of the dopamine transporter gene:
Evidence for allelic heterogeneity. Am J Med Genet B Neuropsychiatr
Genet [Epub ahead of print].
Castellanos FX, Tannock R. 2002. Neuroscience of attention-deficit/hyper-
activity disorder: The search for endophenotypes. Nat Rev Neurosci
3:617–628.
Conners K. 1996. Rating scales in ADHD. Durham, North Carolina: Duke
University Medical Center.
Cornish KM, Manly T, Savage R, Swanson J, Morisano D, Butler N, Grant C,
Cross G, Bentley L, Hollis CP. 2005. Association of the dopamine
transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and
response inhibition in a general population sample. Mol Psychiatry
10:686–698.
Curran S, Mill J, Tahir E, Kent L, Richards S, Gould A, Huckett L, Sharp J,
Batten C, Fernando S, et al. 2001. Association study of a dopamine
transporter polymorphism and attention deficit hyperactivity disorder
in UK and Turkish samples. Mol Psychiatry 6:425–428.
Demiralp T, Herrmann CS, Erdal ME, Ergenoglu T, Keskin YH, Ergen M,
Beydagi H. 2007. DRD4 and DAT1 polymorphisms modulate human
gamma band responses. Cereb Cortex 17:1007–1019.
Diamond A. 2007. Consequences of variations in genes that affect dopamine
in prefrontal cortex. Cereb Cortex 17:i161–i170.
Durston S, Fossella JA, Casey BJ, Hulshoff Pol HE, Galvan A, Schnack HG,
Steenhuis MP, Minderaa RB, Buitelaar JK, Kahn RS, et al. 2005.
Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray
matter volumes in a sample of subjects with attention deficit hyper-
activity disorder, their unaffected siblings, and controls. Mol Psychiatry
10:678–685.
Durston S, Fossella JA, Mulder MJ, Casey BJ, Ziermans TB, Vessaz N, Van
Engeland H. 2008. Dopamine transporter genotype conveys familial risk
of attention-deficit/hyperactivity disorder through striatal activation.
J Am Acad Child Adolesc Psychiatry 47:61–67.
Elia J, Devoto M. 2007. ADHD genetics: 2007 update. Curr Psychiatry Rep
9:434–439.
Faraone SV, Biederman J, Monuteaux MC. 2000. Towards guidelines for
pedigree selection in genetic studies of attention deficit hyperactivity
disorder. Genetic Epidemiology 18:1–16.
Faraone SV, Doyle AE, Mick E, Biederman J. 2001. Meta-analysis of the
association between the 7-repeat allele of the dopamine D4 receptor gene
and attention deficit hyperactivity disorder. Am J Psychiatry 158:1052–
1057.
Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA,
Sklar P. 2005. Molecular genetics of attention-deficit/hyperactivity
disorder. Biol Psychiatry 57:1313–1323.
Fossella J, Sommer T, Fan J, Wu Y, Swanson JM, Pfaff DW, Posner MI. 2002.
Assessing the molecular genetics of attention networks. BMC Neurosci
3:14.
Genro JP, Roman T, Zeni CP, Grevet EH, Schmitz M, de Abreu PB, Bau CH,
Rohde LA, Hutz MH. 2006. No association between dopaminergic
polymorphisms and intelligence variability in attention-deficit/hyper-
activity disorder. Mol Psychiatry 11:1066–1067.
Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. 1996. Hyper-
locomotion and indifference to cocaine and amphetamine in mice lacking
the dopamine transporter. Nature 379:606–612.
Goodman R. 1997. The strengths and difficulties questionnaire: A research
note. J Child Psychol Psychiatry 38:581–586.
Gottesman II, Gould TD. 2003. The endophenotype concept in psychiatry:
Etymology and strategic intentions. Am J Psychiatry 160:636–645.
Kim J, Kim B, Cho S. 2006. The dopamine transporter gene and the
impulsivity phenotype in attention deficit hyperactivity disorder: A case-
Neuropsychological Measures and DAT1 in ADHD 1545
control association study in a Korean sample. J Psychiatr Res 40:730–
737.
Lasky-Su J, Banaschewski T, Buitelaar J, Franke B, Brookes K, Sonuga-
Barke E, Ebstein R, Eisenberg J, Gill M, Manor I, et al. 2007. Partial
replication of a DRD4 association in ADHD individuals using a
statistically derived quantitative trait for ADHD in a family-based
association test. Biol Psychiatry 62:985–990.
Laucht M, Skowronek MH, Becker K, Schmidt MH, Esser G, Schulze TG,
Rietschel M. 2007. Interacting effects of the dopamine transporter gene
and psychosocial adversity on attention-deficit/hyperactivity disorder
symptoms among 15-year-olds from a high-risk community sample.
Arch Gen Psychiatry 64:585–590.
Li D, Sham PC, Owen MJ, He L. 2006. Meta-analysis shows significant
association between dopamine system genes and attention deficit
hyperactivity disorder (ADHD). Hum Mol Genet 15:2276–2284.
Loo SK, Specter E, Smolen A, Hopfer C, Teale PD, Reite ML. 2003.
Functional effects of the DAT1 polymorphism on EEG measures in
ADHD. J Am Acad Child Adolesc Psychiatry 42:986–993.
Loo SK, Rich EC, Ishii J, McGough J, McCracken J, Nelson S, Smalley SL.
2008. Cognitive functioning in affected sibling pairs with ADHD:
Familial clustering and dopamine genes. J Child Psychol Psychiatry
[Epub ahead of print].
Madras B, Miller G, Fischman A. 2005. The dopamine transporter and
attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1397–1409.
Maher BS, Marazita ML, Ferrell RE, Vanyukov MM. 2002. Dopamine
system genes and attention deficit hyperactivity disorder: A meta-
analysis. Psychiatr Genet 12:207–215.
Mill J, Asherson P, Browes C, D’Souza U, Craig I. 2002. Expression of the
dopamine transporter gene is regulated by the 30-UTR VNTR: Evidence
from brain and lymphocytes using quantitative RT-PCR. Am J Med
Genet 114:975–979.
Mill J, Caspi A, Williams BS, Craig I, Taylor A, Polo-Tomas M, Berridge CW,
Poulton R, Moffitt TE. 2006. Prediction of heterogeneity in intelligence
and adult prognosis by genetic polymorphisms in the dopamine system
among children with attention-deficit/hyperactivity disorder. Arch Gen
Psychiatry 63:462–469.
Mitchell RJ, Howlett S, Earl L, White NG, McComb J, Schanfield MS,
Briceno I, Papiha SS, Osipova L, Livshits G, et al. 2000. Distribution of
the 30 VNTR polymorphism in the human dopamine transporter gene in
world populations. Hum Biol 72:295–304.
Nakatome M, Honda K, Tun Z, Kato Y, Harihara S, Omoto K, Misawa S,
Gerelsaikhan T, Nyamkhishig S, Dashnyam B, et al. 1996. Genetic
polymorphism of the 30 VNTR region of the human dopaminergic
function gene DAT1 (human dopamine transporter gene) in the
Mongolian population. Hum Biol 68:509–515.
Oh KS, Shin DW, Oh GT, Noh KS. 2003. Dopamine transporter genotype
influences the attention deficit in Korean boys with ADHD. Yonsei Med J
44:787–792.
Raymond M, Rousset F. 1995. GENEPOP (Version 1.2): Population genetics
software for exact tests and ecumenicism. J Hered 86:248–249.
Rommelse NNJ, Oosterlaan J, Buitelaar J, Faraone SV, Sergeant JA. 2007a.
Time reproduction in children with ADHD and their non-affected
siblings. J Am Acad Child Adolesc Psychiatry 46:582–590.
Rommelse NNJ, Altink ME, De Sonneville LMJ, Buschgens CJM, Buitelaar
J, Oosterlaan J, Sergeant JA. 2007b. Are motor inhibition and cognitive
flexibility dead ends in ADHD? J Abnorm Child Psychol 35:957–
967.
Rommelse NNJ, Altink ME, Oosterlaan J, Buschgens CJM, Buitelaar J, De
Sonneville LMJ, Sergeant JA. 2007c. Motor control in children with
ADHD and non-affected siblings: Deficits most pronounced using left
hand. J Child Psychol Psychiatry 48:1071–1079.
Rommelse NNJ, Altink ME, Oosterlaan J, Buschgens CJM, Buitelaar J,
Sergeant JA. 2008a. Support for an independent familial segregation of
executive and intelligence endophenotypes in ADHD-families. Psychol
Med [epub ahead of print].
Rommelse NNJ, Altink ME, Oosterlaan J, Beem L, Buschgens CJM,
Buitelaar J, Sergeant JA. 2008b. Speed, variability, and timing of motor
output in ADHD: Which measures are useful for endophenotypic
research? Behav Genet 38:121–132.
Rommelse NNJ, Altink ME, Martin NC, Buschgens CJM, Faraone SV,
Buitelaar JK, Sergeant JA, Oosterlaan J. 2008c. Relation between
endophenotype and phenotype in ADHD. Behav Brain Funct 4:4.
Rueda MR, Rothbart MK, McCandliss BD, Saccomanno L, Posner MI. 2005.
Training, maturation, and genetic influences on the development of
executive attention. Proc Natl Acad Sci USA 102:14931–14936.
Schaid JD, Rowland CM, Tines DE, Jacobson RM, Poland GA. 2002. Score
tests for association between traits and haplotypes when linkage phase
is ambiguous. Am J Hum Genet 70:425–434.
Scheres A, Milham MP, Knutson B, Castellanos FX. 2007. Ventral striatal
hyporesponsiveness during reward anticipation in attention-deficit/
hyperactivity disorder. Biol Psychiatry 61:720–724.
Scherk H, Backens M, Schneider-Axmann T, Kraft S, Kemmer C, Usher J.
2007. Dopamine transporter genotype influences N-acetyl-aspartate in
the left putamen. World J Biol Psychiatry [epub ahead of print].
Schott BH, Seidenbecher CI, Fenker DB, Lauer CJ, Bunzeck N, Bernstein
HG, Tischmeyer W, Gundelfinger ED, Heinze HJ, Du¨zel E. 2006. The
dopaminergic midbrain participates in human episodic memory for-
mation: Evidence from genetic imaging. J Neurosci 26:1407–1417.
Sinnwell JP, Schaid DJ. 2005. http://mayoresearch.mayo.edu/mayo/
research/biostat/schaid.cfm.
Sklar P. 2005. Principles of haplotype mapping and potential applications to
attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1357–1366.
Sonuga-Barke EJS. 2002. Psychological heterogeneity in AD/HD—A dual
pathway model of behaviour and cognition. Behav Brain Res 130:29–36.
Sonuga-Barke EJS. 2005. Causal models of attention-deficit/hyperactivity
disorder: From common simple deficits to multiple developmental
pathways. Biol Psychiatry 57:1231–1238.
Sonuga-Barke EJS, Brookes KJ, Buitelaar J, Anney R, Bitsakou P, Baeyens
D, Buschgens C, Chen W, Christiansen H, Eisenberg J, et al. 2008.
Intelligence in DSM-IV combined type attention-deficit/hyperactivity
disorder is not predicted by either dopamine receptor/transporter genes
or other previously identified risk alleles for attention-deficit/hyper-
activity disorder. Am J Med Genet Part B 147B:316–319.
Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S,
Murias M, Moriarity J, Barr C, Smith M, et al. 2000. Dopamine genes
and ADHD. Neurosci Biobehav Rev 24:21–25.
Szobot C, Roman T, Cunha R, Acton P, Hutz M, Rohde LA. 2005. Brain
perfusion and dopaminergic genes in boys with attention-deficit/hyper-
activity disorder. Am J Med Genet Part B 132B:53–58.
Taylor EA. 1986. Childhood hyperactivity. Br J Psychiatry 149:562–573.
Thapar A, O’Donovan M, Owen MJ. 2005. The genetics of attention deficit
hyperactivity disorder. Hum Mol Genet 14:R275–R282.
Tobler AR, Short S, Andersen MR, Paner TM, Briggs JC, Lambert SM, Wu
PP, Wang Y, Spoonde AY, Koehler RT, et al. 2005. The SNPlex
genotyping system: A flexible and scalable platform for SNP genotyping.
J Biomol Tech 16:398–406.
Toplak ME, Jain U, Tannock R. 2005. Executive and motivational processes
in adolescents with attention-deficit-hyperactivity disorder (ADHD).
Behav Brain Functions 1:8.
Vandenbergh DJ, Persico AM, Ulh GR. 1992. A human dopamine trans-
porter predicts reduced glycosylation, displays a novel repetitive
element and provides racially-dimorphic Taq IRFL Ps. Mol Brain Res
15:161–166.
Wohl M, Boni C, Asch M, Cortese S, Orejarena S, Mouren MC, Gorwood P,
Purper-Ouakil D. 2008. Lack of association of the dopamine transporter
gene in a French ADHD sample. Am J Med Genet Part B [epub ahead of
print].
Yang B, Chan RCK, Jing J, Li T, Sham P, Chen RYL. 2007. A meta-analysis
of association studies between the 10-repeat allele of a VNTR poly-
morphism in the 30-UTR of dopamine transporter gene and attention
deficit hyperactivity disorder. Am J Med Genet Part B 144B:541–
550.
Zhou K, Chen W, Buitelaar J, Banaschewski T, Oades RD, Franke
B, Sonuga-Barke E, Ebstein R, Eisenberg J, Gill M, et al. 2007.
Genetic heterogeneity in ADHD: DAT1 gene only affects probands
without CD. Am J Med Genet B Neuropsychiatr Genet. [Epub ahead
of print].
1546 Rommelse et al.
